MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-04
DOI
10.1038/s41379-020-00682-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
- (2019) Margaret Moore et al. MODERN PATHOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series
- (2019) Selma Ugurel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer
- (2019) A. Oaknin et al. GYNECOLOGIC ONCOLOGY
- LAG-3 and GAL-3 in Endometrial Carcinoma
- (2019) Lisa A. Friedman et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
- (2019) Shin Hye Yoo et al. Scientific Reports
- Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function
- (2019) Clara Degos et al. Frontiers in Immunology
- Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
- (2019) Weilei Hu et al. Frontiers in Immunology
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
- (2019) Michael Friedrich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
- (2019) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
- (2019) Barry A. Kriegsman et al. JOURNAL OF IMMUNOLOGY
- Optimizing immunotherapy for gynecologic cancers
- (2019) Maria M. Rubinstein et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women
- (2018) Anne M. Mills et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas
- (2018) Anne Mills et al. MODERN PATHOLOGY
- PD-L1 and IDO Expression in Cervical and Vulvar Invasive and Intraepithelial Squamous Neoplasias: Implications for Combination Immunotherapy
- (2018) Zachary Chinn et al. HISTOPATHOLOGY
- Natural Killer Cells: Development, Maturation, and Clinical Utilization
- (2018) Alex M. Abel et al. Frontiers in Immunology
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
- (2017) Francisco Perea et al. Oncotarget
- Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
- (2017) Roman Groisberg et al. Journal for ImmunoTherapy of Cancer
- Lynch Syndrome Screening in the Gynecologic Tract
- (2016) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings
- (2016) Christine M. Bestvina et al. ONCOLOGIST
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
- (2014) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
- (2014) Yuichiroh Umemoto et al. JOURNAL OF GASTROENTEROLOGY
- Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas
- (2012) Renske A. de Jong et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More